Company profile for Replay Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA. The Company has assembled a toolkit of disruptive platform technologies – including a high payload capacity HSV platform, a hypoimmunogenic platform, and a genome writing platform – to address the scientific challenges currently limiting clinical progress and preventing ge...
Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA. The Company has assembled a toolkit of disruptive platform technologies – including a high payload capacity HSV platform, a hypoimmunogenic platform, and a genome writing platform – to address the scientific challenges currently limiting clinical progress and preventing genomic medicine from realising its full potential.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Unit 120 5555 Oberlin Drive San Diego CA 92121
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Replay wins IND clearance for PRAME T cell cancer therapy
Replay wins IND clearance for PRAME T cell cancer therapy

01 May 2024

// PHARMACEUTICAL TECHNOLOGY

https://www.pharmaceutical-technology.com/news/replay-wins-ind-clearance-for-prame-t-cell-cancer-therapy/

PHARMACEUTICAL TECHNOLOGY
01 May 2024

https://www.globenewswire.com/news-release/2024/04/30/2872029/0/en/Replay-and-MD-Anderson-announce-FDA-clearance-of-IND-application-for-first-in-class-PRAME-targeted-T-Cell-Receptor-Natural-Killer-TCR-NK-cell-therapy-for-hematological-malignancies.html

GLOBENEWSWIRE
30 Apr 2024

https://www.globenewswire.com//news-release/2024/03/11/2843634/0/en/Replay-s-cell-therapy-product-company-Syena-announces-first-patient-dosed-in-Phase-1-2-study-of-TCR-NK-cell-therapy-for-multiple-myeloma.html

GLOBENEWSWIRE
11 Mar 2024

https://www.globenewswire.com//news-release/2023/12/18/2797661/0/en/Replay-s-oncology-focused-product-company-Syena-and-Miltenyi-Biotec-enter-into-exclusive-licensing-and-GMP-manufacturing-agreement-for-PRAME-TCR-NK-cell-therapy-based-on-CliniMACS-.html

GLOBENEWSWIRE
18 Dec 2023

https://www.globenewswire.com//news-release/2023/12/18/2797689/0/en/Replay-and-its-engineered-NK-cell-therapy-company-Syena-announce-exclusive-licensing-agreement-with-National-Institutes-of-Health-for-TCRs-targeting-cancer-neoantigens.html

GLOBENEWSWIRE
18 Dec 2023

https://www.globenewswire.com//news-release/2023/09/21/2747189/0/en/Replay-announces-partnership-between-product-company-Syena-and-JURA-Bio-to-advance-T-cell-receptor-NK-therapies-in-cancer.html

GLOBENEWSWIRE
21 Sep 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty